SCHEMBL2362967

SCHEMBL2362967

COc1cc(CNS(C)(=O)=O)c(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.50
ALPL P05186 1/20 0.38
KDM4E B2RXH2 2/20 0.36
HTT P42858 2/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP1A1 P04798 1/20 0.34
HTR2A P28223 1/20 0.34
ERBB2 P04626 1/20 0.33
POLB P06746 1/20 0.32
NR3C1 P04150 1/20 0.32
PGR P06401 1/20 0.32
NR3C2 P08235 1/20 0.32
AR P10275 1/20 0.32
ADRA2A P08913 1/20 0.31
ADRA2C P18825 1/20 0.31
ADRA1D P25100 1/20 0.31
ADRA1A P35348 1/20 0.31
ADRA1B P35368 1/20 0.31
MAPK14 Q16539 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2352735 0.91 CYP3A4 (0.45) CYP3A4ALPLCYP1A1HTR2AERBB2
SCHEMBL2348091 0.90 CYP3A4 (0.51) CYP3A4ALPLKDM4EHPGDSMN1; SMN2
SCHEMBL3312658 0.89 CYP3A4 (0.44) CYP3A4ALPLKDM4EHTTCYP1A1
SCHEMBL3313139 0.87 CYP3A4 (0.45) CYP3A4ALPLKDM4ESMN1; SMN2LMNA
SCHEMBL2362843 0.86 CYP3A4 (0.48) CYP3A4ALPLKDM4EHPGDCYP1A1
SCHEMBL3313231 0.85 CYP3A4 (0.42) CYP3A4HPGDSMN1; SMN2POLBMAPK1
SCHEMBL3314218 0.85 CYP3A4 (0.42) CYP3A4ALPLSMN1; SMN2POLBLMNA
SCHEMBL2350725 0.83 CYP3A4 (0.34) CYP3A4KDM4EHTTHPGDSMN1; SMN2
SCHEMBL3308176 0.83 CYP3A4 (0.42) CYP3A4KDM4ECYP1A1POLB
SCHEMBL3308199 0.82 CYP3A4 (0.35) CYP3A4KDM4EHTTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US disclosed
EP-2350007-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2011-08-03 EP disclosed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US disclosed
WO-2010049331-A1 HETEROCYCLIC ANTIVIRAL ARYLPYRIDONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B CYP3A4 423/4885ALPL 4328/4885KDM4E 2438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.